Novo Nordisk warns of drug shortages, price hikes amid tariff threat
Novo Nordisk (NVO), the maker of popular obesity/diabetes medications Ozempic and Wegovy, warned Thursday that the Trump administration’s proposed tariffs on pharmaceutical goods could cause potential drug shortages and price hikes.
Novo Nordisk to explore how GLP-1 drugs can help patients with addiction
Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst Lange told an online press conference on Thursday.
Novo Nordisk slashes Wegovy price for patients lacking insurance benefits
Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who can’t get the blockbuster drug through insurance.
Novo Nordisk to slash weight-loss drug Wegovy prices
Mounting competition in the sector and rising obesity have led the pharmaceutical company to start selling the drug directly to consumers.
Novo Nordisk to sell Wegovy at discount for cash-paying US customers
Novo Nordisk said on Wednesday it would offer doses of its weight-loss drug Wegovy at a reduced cost of $499 per month for cash-paying customers in the United States, as it looks to stave off growing competition from compounded versions.
Novo Nordisk to explore how obesity drugs can help patients with addiction
Danish obesity drug giant looking at whether its semaglutide drug can reduce cravings associated with addiction
Novo Nordisk to Sell Weight-loss Drug Wegovy Direct to Patients
Novo Nordisk A/S is following in rival Eli Lilly & Co.’s footsteps by selling its hit weight-loss drug Wegovy directly to US patients at a discount.
Novo Nordisk Drops Price of Weight-Loss Drug Wegovy for Some Patients Paying Out of Pocket
Key Takeaways Novo Nordisk is lowering the price of its weight-loss drug Wegovy to $499 per month for some patients paying out of pocket.The deal is available through the drugmaker's new NovoCare Pharmacy offering.
Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy
The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.
Novo Nordisk Launches Online Pharmacy, Slashes Weight Loss Drug Price
Novo Nordisk (NVO) said Wednesday that it launched a direct-to-patient online pharmacy through which it will offer its weight loss injection at more than half the list price. The company's NovoCare Pharmacy will offer Wegovy directly to cash-paying patients who have been prescribed the treatment but don't have coverage through insurance.
Ozempic, Cetaphil Makers Warn of Impact From Trump Tariffs
The European makers of Ozempic for diabetes and Cetaphil for dry skin said they would feel an impact from President Donald ...
Fierce Pharma3h
In FDA obesity drug battle with compounders, Texas court allows Novo Nordisk to weigh in
As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper ...
Down 39%. Is Novo Nordisk Stock a Buy on the Dip?
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
How Long Should I Stay on Ozempic For Weight Loss?
You know Ozempic can help with weight loss, but how long can you stay on Ozempic exactly? Unfortunately, there isn’t a solid ...
Novo Nordisk Launches National "My Ozempic® Era" Campaign Celebrating Stories of Inspirational Ozempic® Patients
Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...
Tariff wars: Novo Nordisk CEO echoes pharma industry caution on possible drug shortages and price increases
Novo Nordisk warns of potential price hikes and shortages amid global tariff threats, impacting drug prices and supply chains ...
Ozempic maker Novo Nordisk prepared to enter India despite patent expiry, generic competition
Novo Nordisk’s GLP-1 drug Semaglutide, sold under brand names Ozempic and Wegovy, has been hailed as a miracle drug for ...
The Financial Express4h
Novo Nordisk to launch new therapies in blood and growth disorders after success in diabetes and obesity
Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...